Aiming to manufacture sufficient effector cell doses and to evaluate the most promising cell population to target NB, we compared different cell purification (CD56-enriched vs. CD3/CD19-depleted NK cell) and cytokine stimulation procedures (IL-15 vs. IL-2+IL-15) (Figure 1A). This evidence concerns the gene IL15 and neuroblastoma.